A Phase 3 interventional study of SD-101-6.0 cream and Placebo (SD-101-0.0) cream in Epidermolysis Bullosa, sponsored by Scioderm, Inc.. Completed at 38 sites in 13 countries. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2020-04-09.
Sponsored by Scioderm, Inc. (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 3, and was the 10th registered.
86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.
Browse Epidermolysis Bullosa studies →10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 5–21
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Xinnate AB · Sites in United States, France, Greece and 4 more countries
Ages 4+
BioMendics, LLC · Sites in United States
Ages 2+
M. Peter Marinkovich · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 1 Month and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 8
First in 2007; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 15 across 68 interventional studies indexed under Epidermolysis Bullosa.
Median enrollment 16 across the 37 interventional studies, 60 across the 5 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Scioderm, Inc., one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Scioderm, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
BioMarin Pharmaceutical has 5 studies filed under Epidermolysis Bullosa — fewer than ten, so there is no comparison to draw.
6 of the studies in Epidermolysis Bullosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT07027345BioMendics, LLCA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | 2027-01 |
| NCT06834035M. Peter MarinkovichTargeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | 2027-03 |
| NCT07050810Northwestern UniversityThera-Clean® Microbubbles System in Patients With Skin Diseases | 2027-06 |
| NCT06594393Xinnate ABA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim was to assess the efficacy and safety of SD-101-6.0 cream versus Placebo (SD-101-0.0) cream in the treatment of skin lesions in participants with Epidermolysis Bullosa. Funding Source - United States Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD).
This was a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SD-101-6.0 cream versus placebo (SD-101-0.0) cream on skin lesions in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa. Epidermolysis Bullosa is a rare group of inherited disorders that typically manifest at birth as blistering and lesion formation on the skin in response to little or no apparent trauma. In this study, SD-101-6.0 cream or placebo (SD-101-0.0) cream was to be applied topically, once a day to the entire body for a period of 90 days. Participants had 1 target wound selected at baseline by the investigator. The selected target wound was required to have been present for at least 21 days. Photographic confirmation of the target wound location was collected at baseline, and the picture saved from the first visit was used to confirm location of the target wound at subsequent visits. The participant returned to the study site for Visit 2 (approximately 14 days from baseline), Visit 3 (approximately 30 days from baseline), Visit 4 (approximately 60 days from baseline), and Visit 5 (approximately 90 days from baseline) to have the target wound assessed for the level of healing. In addition, itching, pain, body surface area, target wound closure, and scarring of healed target wound were assessed at each visit. The ARANZ SilhouetteStar™ was used to measure the target wound at all visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
Drug: SD-101-6.0 cream
SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
Drug: Placebo (SD-101-0.0) cream
applied topically once a day for 90 days
Also known as: SD-101
applied topically once a day for 90 days
Also known as: placebo
Time To Complete Target Wound Closure Within 3 Months
Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Time to target wound closure was measured from the date of the first administration of the study drug to the date of target wound closure. Participants were censored if they did not have a response within 3 months, or withdrew earlier before the confirmation of their target wound closing. This primary end point displays the mean time to complete target wound closure, analyzed using a Kaplan-Meier approach.
Time frame: From baseline to Month 3 visit
The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months
Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Participants were considered responders if they experienced complete wound closure at the Week 2 or Months 1, 2, or 3 visits. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits. This primary end point displays the percentage of participants from the ITT population who had complete target wound closure by the end of the study period (that is, 3 months). Analysis was performed on participants with post-baseline wound closure data.
Time frame: From baseline to Month 3 visit
Percentage Of Participants Experiencing Complete Closure Of Their Target Wound At Month 1 And Month 2 Visits
Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. The percentage of participants who completed target wound closure at the Month 1 and Month 2 study visits is displayed. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits.
Time frame: From baseline to Month 1 and Month 2 visits
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions.
Time frame: Baseline, Month 3 visit
Change From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit
Total body wound burden was calculated using BSAI. A wound defined as an open area on the skin (that is, epidermal covering disrupted). BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, lower limbs, trunk \[includes groin\]), and multiplied by the weighting factor, then summed for all body regions.
Time frame: Baseline, Month 3 visit
Change From Baseline In Itching Score At Day 7
Itching was assessed using the 5-point Itch Man Pruritus Assessment Tool. For participants up to 5 years of age, itching was assessed using caretaker's response and participants 6 years of age and older self-reported their itching assessments based on the following scores: 0=Comfortable, no itch; 1=itches a little, does not interfere with activity; 2=itches more, sometimes interferes with activity; 3=itches a lot, difficult to be still, concentrate; 4=itches most terribly, impossible to sit still or concentrate. Itching scores were categorized into 3 groups based on improvement; Improved or No Itching, Not Improved, and Missing. An itching score reduction from baseline greater than or equal to 1 point on the scale was classed as improved.
Time frame: Baseline, Day 7
Change From Baseline In Pain Score At Day 7
Change in pain assessed at Day 7 compared to baseline was measured using the Face, Legs, Activity, Cry, and Consolability (FLACC) behavioral scale for participants 1 month to 3 years of age. Each of the 5 FLACC categories was scored from 0 to 2, which resulted in a total score between 0 and 10 with 0=Relaxed and comfortable, 1 to 3=Mild discomfort, 4 to 6=Moderate pain, and 7 to 10=Severe discomfort/pain. For participants 4 years of age and older, the "Wong Faces Pain Scale" was used. This scale shows a series of faces ranging from a happy face at 0, which represents "no hurt," to a crying face at 10, which represents "hurts worst". Pain scores were categorized into 3 groups based on improvement: Improved or No Pain, Not Improved, and Missing. A pain score reduction from baseline greater than or equal to 2 points on the scale was classed as improved.
Time frame: Baseline, Day 7
Of 210 participants screened for this study, 169 participants were randomly assigned, on a 1:1 basis, to treatment with SD-101-6.0 or placebo at 31 study centers in 13 countries. The first participant was enrolled on 11 March 2015 and the last participant completed the study on 05 July 2017.
| Milestone | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| Started | 82 | 87 |
| Received at least 1 dose of study drug | 82 | 87 |
| Completed | 75 | 80 |
| Not completed | 7 | 7 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Returned to previous therapeutic regimen | 0 | 1 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Elective medical treatment | 1 | 0 |
| Withdrew: Non-compliance | 1 | 0 |
Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Time to target wound closure was measured from the date of the first administration of the study drug to the date of target wound closure. Participants were censored if they did not have a response within 3 months, or withdrew earlier before the confirmation of their target wound closing. This primary end point displays the mean time to complete target wound closure, analyzed using a Kaplan-Meier approach.
| days | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| Time To Complete Target Wound Closure Within 3 Months | 41.6 ± 25.50 | 53.6 ± 28.59 |
Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Participants were considered responders if they experienced complete wound closure at the Week 2 or Months 1, 2, or 3 visits. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits. This primary end point displays the percentage of participants from the ITT population who had complete target wound closure by the end of the study period (that is, 3 months). Analysis was performed on participants with post-baseline wound closure data.
| percentage of participants | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months | 49.4 | 53.6 |
Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. The percentage of participants who completed target wound closure at the Month 1 and Month 2 study visits is displayed. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits.
| percentage of participants | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| Month 1 | 31.6 | 22.6 |
| Month 2 | 43.0 | 42.9 |
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions.
| Percentage change in BSAI | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit | -4.637 ± 1.404 | -5.319 ± 1.354 |
Total body wound burden was calculated using BSAI. A wound defined as an open area on the skin (that is, epidermal covering disrupted). BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, lower limbs, trunk \[includes groin\]), and multiplied by the weighting factor, then summed for all body regions.
| Percentage change in BSAI | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| Change From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit | -3.050 ± 0.816 | -2.922 ± 0.813 |
Itching was assessed using the 5-point Itch Man Pruritus Assessment Tool. For participants up to 5 years of age, itching was assessed using caretaker's response and participants 6 years of age and older self-reported their itching assessments based on the following scores: 0=Comfortable, no itch; 1=itches a little, does not interfere with activity; 2=itches more, sometimes interferes with activity; 3=itches a lot, difficult to be still, concentrate; 4=itches most terribly, impossible to sit still or concentrate. Itching scores were categorized into 3 groups based on improvement; Improved or No Itching, Not Improved, and Missing. An itching score reduction from baseline greater than or equal to 1 point on the scale was classed as improved.
| units on a scale | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| Change From Baseline In Itching Score At Day 7 | -0.5 ± 1.31 | -0.3 ± 1.24 |
Change in pain assessed at Day 7 compared to baseline was measured using the Face, Legs, Activity, Cry, and Consolability (FLACC) behavioral scale for participants 1 month to 3 years of age. Each of the 5 FLACC categories was scored from 0 to 2, which resulted in a total score between 0 and 10 with 0=Relaxed and comfortable, 1 to 3=Mild discomfort, 4 to 6=Moderate pain, and 7 to 10=Severe discomfort/pain. For participants 4 years of age and older, the "Wong Faces Pain Scale" was used. This scale shows a series of faces ranging from a happy face at 0, which represents "no hurt," to a crying face at 10, which represents "hurts worst". Pain scores were categorized into 3 groups based on improvement: Improved or No Pain, Not Improved, and Missing. A pain score reduction from baseline greater than or equal to 2 points on the scale was classed as improved.
| units on a scale | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| Change From Baseline In Pain Score At Day 7 | -0.3 ± 2.57 | -0.6 ± 3.07 |
Collected over From baseline up to 3 months.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SD-101-6.0 Cream | 0/82 (0%) | 4/82 (4.9%) | 49/82 (59.8%) |
| Placebo (SD-101-0.0) Cream | 1/87 (1.1%) | 8/87 (9.2%) | 46/87 (52.9%) |
| Event | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| PyrexiaGeneral disorders | 2/82 | 0/87 |
| InfluenzaInfections and infestations | 0/82 | 2/87 |
| WoundInjury, poisoning and procedural complications | 1/82 | 0/87 |
| AggressionPsychiatric disorders | 1/82 | 0/87 |
| AnemiaBlood and lymphatic system disorders | 0/82 | 1/87 |
| Cardiopulmonary failureCardiac disorders | 0/82 | 1/87 |
| DysphagiaGastrointestinal disorders | 0/82 | 1/87 |
| GastritisGastrointestinal disorders | 0/82 | 1/87 |
| Oesophageal stenosisGastrointestinal disorders | 0/82 | 1/87 |
| CystitisInfections and infestations | 0/82 | 1/87 |
| Event | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/82 | 3/87 |
| PruritusSkin and subcutaneous tissue disorders | 9/82 | 8/87 |
| PyrexiaGeneral disorders | 5/82 | 9/87 |
| Skin infectionInfections and infestations | 3/82 | 9/87 |
| Upper respiratory tract infectionInfections and infestations | 4/82 | 9/87 |
| Wound infectionInfections and infestations | 6/82 | 5/87 |
| Staphyloccocal skin infectionInfections and infestations | 1/82 | 6/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/82 | 4/87 |
| PainGeneral disorders | 1/82 | 4/87 |
| Ear infectionInfections and infestations | 1/82 | 4/87 |
The Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream | Total |
|---|---|---|---|
| Mean | 13.8 ± 13.15 | 13.9 ± 13.12 | 13.9 ± 13.09 |
| Sex: Female, Male(Participants) | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream | Total |
|---|---|---|---|
| Female | 33 | 48 | 81 |
| Male | 49 | 39 | 88 |
| Race/Ethnicity, Customized(Participants) | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream | Total |
|---|---|---|---|
| White/Caucasian | 69 | 72 | 141 |
| Black/African American | 5 | 3 | 8 |
| Asian | 4 | 8 | 12 |
| Other | 1 | 1 | 2 |
| Not Reported | 3 | 3 | 6 |
| EB type(Participants) | SD-101-6.0 Cream | Placebo (SD-101-0.0) Cream | Total |
|---|---|---|---|
| Simplex | 10 | 8 | 18 |
| Recessive dystrophic | 57 | 62 | 119 |
| Junctional non-Herlitz | 15 | 17 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Jul 2017, 27 months.
Results were first posted in Oct 2018, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nelitolimod